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Abstract
B ackgrou n d : Currently, two main technologies are used for screening of D N A  copy number; the 
BA C (Bacterial Artificial Chromosome) and the recently developed oligonucleotide-based C G H  
(Chromosomal Comparative Genomic Hybridization) arrays which are capable of detecting small 
genomic regions with amplification or deletion. The correlation as well as the discriminative power 
of these platforms has never been compared statistically on a significant set of human patient 
samples.
Results: In this paper, we present an exhaustive comparison between the two C G H  platforms, 
undertaken at two independent sites using the same batch of D N A  from l9 advanced prostate 
cancers. The comparison was performed directly on the raw data and a significant correlation was 
found between the two platforms. The correlation was greatly improved when the data were 
averaged over large chromosomic regions using a segmentation algorithm. In addition, this analysis 
has enabled the development of a statistical model to discriminate BA C outliers that might indicate 
microevents. These microevents were validated by the oligo platform results.
C o n c lu s io n : This article presents a genome-wide statistical validation of the oligo array platform 
on a large set of patient samples and demonstrates statistically its superiority over the BAC 
platform for the Identification of chromosomic events. Taking advantage of a large set of human 
samples treated by the two technologies, a statistical model has been developed to show that the 
BA C platform could also detect microevents.
Open Access
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Background
The study o f the genom ic imbalances in a variety o f differ­
ent diseases, including cancer, is a major step towards the 
understanding o f  disease development. In cancer cells, for 
example, DNA copy number increases have been shown  
to be one o f the mechanisms by which oncogenes and 
drug resistance genes can be activated, whereas loss o f 
DNA material may cause inactivation o f  tumor suppressor 
genes. Knowledge o f copy-number aberrations can have 
also immediate clinical use in diagnosis and in some cases 
can provide useful prognostic information. Association of 
DNA copy-number aberrations with prognosis has been  
found for a variety o f tumor types, including prostate can­
cer [1], breast cancer [2], gastric cancer [3] and lymphoma 
[4,5].
Chromosomal Comparative Genomic Hybridization 
(CGH) is a molecular cytogenetic m ethod for the detec­
tion o f chromosomal imbalances and it has been exten­
sively used for studying copy number alterations in 
various cancer types since it was first described in 1992 [6­
8]. As classical CGH has an average resolution o f 10-20  
megabases, it is able to detect changes affecting relatively 
large chromosomal regions. The introduction o f array- 
based platforms has therefore greatly improved genomic 
profiling and currently, two technologies are mainly used 
for screening o f  DNA copy number; the BAC (Bacterial 
Artificial Chromosome) and the oligonucleotide-based  
CGH arrays. BAC-based CGH arrays were amongst the 
first genom ic arrays to be introduced [9] and are routinely 
used to detect single copy changes in the genome, owing 
to their high sensitivity. However, producing BAC clones 
for array CGH (aCGH) is expensive and time-consuming 
and, due to the large size o f BACs, the limits o f BAC aCGH 
resolution have been reached. Oligonucleotide aCGH 
[10,11] allow flexibility in probe design, greater coverage, 
and much higher resolution. The latter depends on array 
design and the cell type homogeneity. Moreover, oligonu­
cleotides can more easily be produced for any organism 
for which the genome has been sequenced. Today, as 
noted in [12], the aCGH field is evolving towards oligonu­
cleotide aCGH.
IJssel [13] has published a genome-wide validation o f  
their in-house spotted oligo aCGH using BAC arrays, for 
human and mouse samples. These samples consist o f one 
human gastric tumour and two different mouse tumours, 
and the comparison between BAC and oligo aCGH was 
performed on the genomic profiles. In this study, IJssel 
distinguished two kinds o f noise, the technical noise and 
the true genomic copy number polymorphisms [14]. Var­
ious algorithms for data denoising exist such as the non- 
parametric method called circular binary segmentation 
(CBS) [15] which splits the chromosomes into regions o f
equal copy number. CBS is identified as one o f the best 
segmentation methods [16].
Here, we present a comprehensive comparison between 
the two aCGH platforms using available data from 19 
human advanced prostate cancer (European PRIMA 
project, PRostate cancer Integral Management Approach) 
obtained at two independent sites with the same batch o f  
DNA. This comprehensive comparison has been per­
formed on raw data sets and data analysed using CBS [15]. 
This represents the first genome-wide statistical validation  
o f the oligo array platform. In addition we have developed  
a statistical m ethod to identify BAC outliers that could  
represent microevents.
Results
Probe distribution and noise levels for the BAC and oligo 
platforms
The repartitions o f BACs and oligos on  the human  
genom e were first compared. The uniformity o f the 3040  
BACs and the 40319 oligos repartition along the human  
genom e was tested using the Kolmogorov-Smirnov test 
(p-value < 0.01), considering each chromosome arm as an 
interval and each BAC and oligo as a point. BACs are uni­
formly distributed along all the chromosomes whereas 
oligos are not, except on chromosome 18 and arms 7p, 
10p and 19p.
Figure 1 illustrates the data from both platforms for the 
same patient sample (819) along the human genome. 
Both platforms detect aberrations, for instance on chro­
m osom es 8, 10 and 11, and the log-ratios o f both plat­
forms oscillate around stable values. To measure the 
noise, we have computed the autocorrelation o f the log- 
ratios inside each chromosome and found 0.36 and 0.18 
for BAC and oligo aCGH data, respectively. This implies 
that there is more baseline Variation in  oligo-based aCGH 
data compared to BAC aCGH data.
A log-ratio comparison of the oligo and BAC CGH  
platforms
The comparison was restricted to the 22 autosomes as the 
available data were produced with the sex mismatch for 
BAC aCGH and not for oligo aCGH. Each BAC value was 
compared with the log-ratios o f  the corresponding oligos, 
i.e oligos positioned between the start and the end o f the 
BAC. This comparison is not straight-forward as the mean 
number o f oligos per BAC across the 19 patients is only 
2.5. The details o f the distribution o f the number o f oligos 
per BAC are shown in figure 2. A one-sample Student test 
was performed for the 1345 BACs that overlap with at 
least 10 oligos, so that the test had enough power. There 
were 32 BAC log-ratios significantly different from their 
corresponding oligo log-ratios (p-value < 0.01). To pro­
vide a more global comparison, a complementary analysis
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F ig u r e !
G e n o m ic  d ata  d isp lay fo r  B A C  and o ligo  a C G H  data. The bottom plot represents BA C aCG H  data on the human 
genome and the upper one the oligo aCG H  data for the same patient sample (8I9). Red dotted-line on the two aC G H  plots 
indicates two copies. The sex mismatch was performed for the BA C aCG H  but not for the oligo.
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F ig u re 2
D istrib u tio n  o f th e  n u m b er o f o ligos p e r B A C  fo r  all 
th e  19 p atien t sam ples. 9975 BACs have no oligos and 
1345 have at least IG oligos.
was carried out on the 43372 BAC values corresponding 
to at least one oligo in the 19 patients. The comparison 
was done by Computing the Kendall correlation for all 
pairs o f BAC and oligo log-ratios, the oligo value being 
a mean oligo log-ratio. The pair values are plotted on fig­
ure 3. The correlation gives a significant p-value inferior 
to 1e  - 15 with t  = 0.37. A rvalue o f 0.37 indicates that 
both values o f a pair increase or decrease with a proba­
bility o f 68.5%. When the Kendall's correlation test is 
performed excluding BACs containing fewer than 6 oli­
gos, t  reaches 0.44. This comparison shows that there is 
a significant correlation between the BAC and the oligo 
platform results.
BAC log-ratios
F ig u re 3
D o tp lo t o f B A C  lo g-ratio s versu s o ligo  log-ratios. The
dot-plot has been done for the 43372 BACs of the I9 
patients having at least one corresponding oligo.
0
Page 3 of 10
(page number not for citation purposes)
BMC Genomics 2007, 8:84 http://www.biomedeentral.eom/1471 -2164/8/84
Comparison between oligo and BAC CGH using 
segmentation
Oligo and BAC CGH platforms were compared after seg­
mentation into regions o f equal copy number as the indi­
vidual number o f  copies can be corrupted with noise. The 
Circular Binary Segmentation m ethod (CBS) [15] was 
used both for BAC and oligo data. This is illustrated in fig­
ure 4 for chrom osome 3 from patient 817.
A statistical comparison was performed to assess the diver­
gence o f the BAC and oligo data in the regions delimited 
by the segmentation. Each segment is considered as a log- 
ratios sample and two comparisons were made. Firstly, we 
compared globally all the BAC and oligo Segments. Each 
BAC segment was compared with the corresponding oli-
gos, located between the start and the end o f  the BAC seg­
ment. This was also done reciprocally with the oligo 
Segments as the starting point, as the comparison is asym­
metrical. The pair segment mean values o f all patient sam­
ples are shown in figure 5. The Kendall correlation gives a 
p-value inferior to 1e  - 15, with t  significantly greater 
(0.81 and 0.80 for BAC and oligo Segments respectively) 
than the value o f 0.37 achieved without segmentation.
Secondly, all the segments were compared individually. 
Before comparing the segment samples, a Shapiro test was 
performed to determine whether their distributions are 
gaussian. A Student test was used to compare the Gaussian 
distributions, otherwise a Wilcoxon-Mann-Whitney test 
was applied. A 1% false discovery rate [17] was then used
F ig u r e 4
C h ro m o so m ic  d ata  d isp lay fo r  B A C  a C G H  d ata and o ligo  a C G H  data. From bottom to top are represented on chro­
mosome 3 of patient sample 8I7, the BA C aCG H  data plot, the oligo aCG H  data plot, the segmented BA C data plot, the seg­
mented oligo data plot, the C G H  BACs (in blue are represented the BAC outliers), the C G H  oligonucleotides and the genes. 
The black dotted boxes indicate the different regions of detected BA C outliers ( I ,  2, 3, 4, 5 and 6).
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G lo b a l co m p ariso n  betw een B A C  and o ligo  S e g ­
m ents. The reference segments obtained by CBS [15] are 
BACs on the top plot and oligo on the bottom.
to avoid problems related to multiple testing. Using these 
approaches we have identified 173 o f 1231 (14%) BAC 
segments with values divergent from oligo values (BAC 
versus oligo) and 177 o f 1560 (11%) oligo divergent seg­
ments (oligo versus BAC). To complete this result the 
same comparison was done with a false discovery rate of 
5% and 10%. For 5% the number o f divergent segments 
are then 272 and 338 for BAC versus oligo and oligo ver­
sus BAC respectively and for 10%, 299 and 375.
Finally, the comparison o f the two platforms was focused 
on the detection o f aberrant events. We considered as 
aberrations all segments with mean number o f copies 
lower than 1.5 or higher than 2.5. The BAC platform 
detected 71 deletions and 74 amplifications among the 19 
patient samples whereas the oligo platform detected 314 
deletions and 209 amplifications with median lengths of  
12 Mbp and 3.5 Mbp respectively. This shows that oligo 
aCGH detect more, smaller chromosomal events than
BAC aCGH. Regarding the genomic location o f these seg­
ments, 40 segments were found by both platforms either 
deleted or amplified with an overlapping region compris­
ing more than 90% o f each segment. It is important to 
note that their median length is 27 Mbp, indicating that 
large chromosomal aberrations are found by both plat­
forms.
In conclusion, segmentation enhances the correlation 
between the two platforms. Another result is that the oligo 
aCGH reveal many more, smaller aberrations.
Detection of outliers in BAC segments
In order to perform a more in-depth analysis o f both plat­
forms, that could then be applied to the identification o f  
target genes and regions o f  genetic alteration, we devel­
oped a statistical m odel to detect BAC outliers and vali­
dated the results with the oligo CGH platform. An 
advantage o f the oligo CGH platform is its ability to detect 
microevents. In this section we show that, to some extent, 
the BAC aCGH platform, and more precisely BAC outliers 
within segments, could indicate microevents.
BAC outliers can be detected by m odelling their log-ratios 
with a Gaussian distribution N (ds, a )  where d s is the the­
oretical mean o f the BAC segment s and a  the Standard 
deviation across all segments and all patients. However to 
avoid misestimating a  by including too many outliers, 
this parameter has been estimated on the least varying 
patient, 812, containing n  = 3017 BACs. Let f i  s and 6  be 
the estimators o f d s and a.  To detect outliers the following  
classical calculus was performed considering each BAC 
value x inside its corresponding segment s o f  size n s. For 
each BAC, d  was reestimated by Computing a new /us on  
the n s - 1 value left after excluding the x value.
x - f i s = x - f i s -  (fis - f i s ) « J n s -  1(x - f i s ) J n s -  1(x - f i s ) J n s -  1(fis - f i s )
J n s -  1(x - f i s ) , J n s -  1(fis - f i s ) ,As —-------------------- and —---------------------  obey asymp-
6 6
totically the N (0, ^ j n s - 1 ) and N (0,1) law respectively,
J n s - 1(x -  f i , ) .—  the distribution o f —-------------------  is the N (0, J n s ) law.
6
n 6Besides, it is known that the law o f ------ is asymptotically
6
6 6 6
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J n s - 1(x -  f i s )
2
X n - \ . From this it is inferred that: t  =  ■
n 6
( n  - 1)6^
obeys asymptotically a Student's law T n-1. t  is simplified to
x -  u s ( n s -  1)(n- 1 )  A: t  = --------- ------------------- . A p-value is computed for
6  y  n s n
each BAC using the following procedure:
For each segment do
For each BAC inside current segment do
Produce a sample o f all the segment log-ratios except 
the current BAC one
Compute a p-value for the BAC value x  according to 
formula
Tn -1  -  'x -  f is  ( n s -  1)(n -  1)
Done
Done
All p-values are treated according to [17] taking F D R  = 
1%.
This m odel was used on  the 19 patient samples. 990 out­
liers were detected in the genomic profiles o f the patients, 
across all the chromosomes. Figure 4 shows 4 isolated 
BAC outliers (boxes 1, 2, 3 and 5) and two groups o f  BAC 
outliers (boxes 4 and 6) on chromosome 3 o f patient sam­
ple 817. Isolated BAC outliers point to putative micro­
events (microdeletion or small amplification) whereas 
groups o f BAC outliers may indicate larger aberred 
regions. Finally to validate statistically this result, the Ken­
dall's correlation with oligos was computed for the 749 
BAC outliers with at least one corresponding oligo giving 
t  = 0.54 and a p-value o f  1 e  - 15.
Discussion
The conceptual advantage o f a high density oligo aCGH is 
that it can reveal microdeletions or amplifications at the 
gene level that may contribute to gene transcript Variation 
and that are not detected on a BAC platform. Indeed the 
oligo platform has an average 35 kbp spatial resolution 
that enables to span all the well characterised genes 
(defined in NCBI build 35, May 2004) providing suffi­
cient coverage for a genome wide survey o f DNA aberra­
tions. Different sizes o f  microdeletions, from 2 to 7 
probes have been detected by the CBS method, such as the 
microdeletion containing the potential tumor suppressor 
ATBF1 [18].
In this paper, oligo aCGH results are validated using the 3 
k BAC aCGH platform on data from 19 patients. The clin­
ical material used in the PRIMA project is extremely unu­
sual, displaying greater than 75% tumour cellularity. In 
general, other than in very advanced cancers, the level o f  
tumour cellularity would be significantly lower for pros­
tatic material and this together with lymphocytic infiltra­
tion might be expected to add to the noise com ponent o f  
the oligo aCGH signal and reduce concordance both with 
BAC array data and gene expression microarrays. The 
number o f  patients involved in this experiment allowed 
us to perform statistically significant analyses. Indeed 
there are 1345 BACs that overlap with at least 10 oligos 
and 43372 BACs with at least one oligo in the 19 patients.
The validation was first carried out directly, by matching 
each BAC to the corresponding oligo raw data, and then 
indirectly, using a segmentation algorithm called CBS 
[15], which gave more significant results.
The Kendall's correlation on the raw data was significant, 
with t  = 0.37, and was improved by segmentation, reach­
ing a value o f 0.8. Correlation was therefore increased 
more than two fold when compared to the direct compar­
ison, confirming the observation o f IJssel [13], that BAC 
and oligo profiles are very similar after smoothing. This 
global analysis o f all BAC and oligo Segments was com ­
plemented by an individual comparison, where each seg­
m ent from BAC or oligo platforms was tested against its 
corresponding oligo or BAC data set. 14% and 11% o f  
BAC and oligo segments respectively were found to be 
divergent. These percentages can be lowered (10% and 
7%) by scaling the oligo values as the log-ratios are higher 
for oligos than for BACs again in agreement with IJssel 
[13] (figure 5). However these statistical tests only reveal 
very divergent segments, indeed taking false discovery 
rates equal to 5 or 10% gives higher percentages (22% and 
19%, 27% and 22% respectively). So this number o f  
divergent segments should be regarded as a lower bound. 
Indeed there were only few similar copy number aberra­
tions between the two platforms as the oligo platform pre­
sented the advantage to detect more, smaller 
chromosomic aberrations. Secondly, we compared the 
noise level between the two platforms on raw and seg­
mented data. Computing the autocorrelation along each 
chromosome, we observed that the baseline variation for 
BACs is lower than for oligos in agreement with previous 
studies by IJssel [13] and Ylstra [12] who both computed  
the standard deviation on regions without copy number 
changes. Using the regions o f equal copy numbers pro­
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duced by CBS, the means o f the oligo and BAC segments 
standard deviations have been computed giving respec­
tively 0.32 and 0.10 confirming the previous result. BACs 
with large insert clones display a lower variation com ­
pared with the oligo platform. However, the trade-off is a 
lower sensibility for BACs compared to oligos. Besides, 
the standard deviation value o f  0.32 o f the oligo platform, 
is small from a statistical point o f view. Indeed, the confi­
dence interval o f the true number o f copies inside seg­
ments is small. For instance for a segment with 10 oligos 
inside, a standard deviation o f 0.32 means that for a mean 
value o f 3 copies, the interval is 2.5 -  3.6 (probability = 
99%).
In spite o f the many advantages o f  the oligo aCGH plat­
form, there is still som e value in using the BAC platform. 
BACs are distributed uniformly on the human genom e so 
that regions not previously found to be involved in cancer 
or non-coding regions are covered. This te rra  in c o g n i ta  
may be interesting for further investigation, in particular 
to search for microRNAs and repeated sequences. In addi­
tion, a BAC outlier detection m odel that could point to 
putative microevents has been introduced in this article. 
The BAC outlier values have been compared with the cor­
responding oligo values with good correlation. A large 
number o f these BAC outliers (35%) were found in 
regions without known genes according to UCSC (June 
2005). However these BAC outliers represent large regions 
o f 150 kbp and the potential microevents must still be 
precisely located and biologically validated.
Conclusion
We have performed a large scale comparison o f  oligo and 
BAC platforms using a set o f 19 patient samples. First, we 
have established statistically the reliability o f the oligo 
platform for the identification o f chromosomic events. 
Moreover the oligo platform outperforms the BAC tech­
nology for the detection o f more, smaller aberrations. 
Taking advantage o f this large set o f data, we have devel- 
opped a statistical model, that highlights that BACs may 
detect putative microevents. Hopefully, this result will 
incite researchers to reconsider the potential use o f  BAC 
data for more in-depth investigation o f new data, as well 
as for the numerous publically available BAC CGH data. 
The challenge in future studies will be the routine estab­
lishm ent o f banks o f well-defined laser captured material, 
so that the greater sensitivity o f these platforms can be suc­
cessfully exploited. In order to obtain a more complete 
picture o f cancer, attempts could then be made to com ­
bine the aCGH approaches with transcriptomic and pro- 
teomic technologies.
Methods
Prostate cancer samples and DNA extraction
The analyzed sample set is com posed o f 19 advanced 
prostate cancer samples from 18 patients. Frozen tissue 
blocks were step-sectioned using a cryostat, and 20 d m  
sections were collected in frozen tubes for subsequent 
DNA and RNA extractions.
Isolation o f DNA
DNA was extracted from the samples after overnight pro­
teinase K treatment using standard protocols [19]. For all 
samples, the same batch o f DNA was used for both BAC 
and oligo aCGH analyses to make the data comparable.
BAC aCGH plateform
BAC clones were selected from RP-1, RP-5 and RP-6, RP-
11 [20] and CalTech BAC [21]. The clones were selected 
from the published Golden Path and spaced at approxi­
mately 1-Mb intervals across the arm o f each chromo­
some. Drosophila BACs were obtained from the RPCI-98 
library [20]. All clones were screened for T1 phage con­
tamination, streaked to a single colony, and verified by 
fingerprinting. Clone details can be obtained from the 
Ensembl database accessed in the CytoView pages [22]. 
The resultant 1 Mb whole-genom e BAC aCGH has been  
previously described [19].
DNA was labeled by use o f  a Bioprime Labeling Kit (Inv- 
itrogen, Carlsbad, CA) with modification o f the nucleo­
tide mix. Briefly, a 84 d  reaction was set up containing 
600 ng o f  DNA and a final concentration o f 1 x Random 
Primers Solution. After denaturing the DNA for 10 m in at 
100°C, 10 d  l0 x dNTP mix (0.5 mM dCTP, 2 mM dATP,
2 mM dGTP, 2 mMdTTP in TE-buffer), 4 d  1 mM Cy5- 
dCTP or Cy3-dCTP (NEN Life Science Products, Boston, 
MA) and 2 d  Klenow fragment supplied in the kit were 
added on ice to produce a final reaction volum e o f 100 d .  
The reaction was incubated at 3 7 °C overnight and 
stopped by adding 10 d  stop buffer (Bioprime Labeling 
Kit; Invitrogen). Unincorporated nucleotides were 
removed by use o f microspin G50 columns (Pharmacia 
Biotech, Piscataway, NJ) according to the instruction o f  
the suppliers.
The arrays have an area 3 x 2 cm. Female genomic DNA 
was used as reference. Test and reference DNA (180 d  
each) were combined, precipitated together with 135 d  o f  
human Cot1 DNA (Invitrogen), and resuspended in 60 d  
o f hybridization buffer (50% formamide, 10% dextran 
sulfate, 0.1% Tween 20, 2 SSC, and 10 mM Tris/HCl, pH 
7.4) and 3 d  o f yeast tRNA (100 d g/d ; Invitrogen). A ring 
o f rubber cement was closely applied around the array to 
form a well. After denaturing the sample for 10 m in at 
72°C, the denatured herring sperm Cot1 DNA mix was 
added and the array incubated in a humidity chamber
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containing 3 MM paper (Whatmann, Hillsboro, OR) sat­
urated with 2 x SSC and 40% formamide on a table rock­
ing at 5 rpm at 3 7 °C for 60 min. Arrays were 
prehybridized as follows: 80 d  o f herring sperm DNA (10  
mg/ml; Sigma) and 135 d  o f human Cot1 DNA (Invitro­
gen) were precipitated, resuspended in 80 d  o f hybridiza­
tion buffer, and denatured for 10 m in at 72 °C. The 
prehybridization solution was then removed and replaced 
by the prehybridized genom ic DNA. The slide was trans­
ferred into a small hybridization chamber containing 
Whatmann 3 MM paper saturated with 2 x SSC and 20% 
formamide, sealed with parafilm, and incubated on a 
rocking table (5 rpm) at 3 7 °C for 48 hr. Slides were 
washed for 10 m in at room temperature in PBS 0.05%  
Tween 20, 30 m in at 42°C  in 50% formamide 2 x SSC, 
and 10 m in at room temperature in PBS 0.05% Tween 20, 
before being dried by spinning in a centrifuge for 5 m in at 
150 g and stored until scanning.
Arrays were scanned by use o f an Axon 4000B scanner 
(Axon Instruments, Burlingame, CA). Images were ana­
lyzed by use o f GenePix Pro 3.0 software (Axon Instru­
ments). Spots were defined by use o f the automatic grid 
feature o f the software and manually adjusted where nec­
essary. Fluorescence intensities o f all spots were then cal­
culated after subtraction o f local background. To correct 
for non-specific hybridization to spotted DNA, the mean 
intensity o f all o f the Drosophila clones was subtracted for 
each fluorochrome from each o f  the human clones before 
ratio calculation (Drosophila correction).
Oligo aCGH platform
Oligonucleotide aCGH was performed according to the 
protocol provided by Agilent Technologies (oligonucle­
otide aCGH for genomic DNA analysis, protocol version 
2.0, August 2005, Agilent Technologies, Palo Alto, CA), 
with minor modifications. Briefly, 12 dg o f  genomic DNA 
was digested overnight with AluI and RsaI followed by 
purification using phenol-chloroform extraction. Male 
genomic DNA (catalog number G1471, Promega, Madi­
son, WI) was used as reference in all hybridizations in 
order to analyse the chromosome X as its related copy 
number alterations play a key role in prostate cancer. 3 d g 
o f digested tumour DNA and reference DNA was labeled 
with Cy5-dUTP and Cy3-dUTP (PerkinElmer, Wellesley, 
MA), respectively, in a random priming reaction using 
Bioprime Array CGH Genomic Labeling Module (Invitro­
gen, Carlsbad, CA). After labeling tumor DNA and refer­
ence DNA samples were pooled, cleaned and 
hybridization cocktails were prepared as instructed in the 
protocol. Hybridization and washes were performed 
according to the protocol using the human genome CGH 
44B oligo microarrays (catalog number G 4410-60520 by 
Agilent Technologies). A laser confocal scanner (Agilent 
Technologies) was used to obtain signal intensities from
targets, and Feature Extraction software (version 8.1.1.1, 
Agilent Technologies) was applied in image analysis using 
manufacturer's recommended settings
(44K_CGH_0605). To analyze the aCGH data we used 
CGH Analytics software (version 3.2.32, Agilent Technol­
ogies). Quality metrics provided by CGH Analytics were 
evaluated to ensure good data quality.
Array CGH data visualisation
The visualisation tool called CGHviewer was written in  
Tcl/Tk. It was developed within the Gscope platform 
(Ripp et al., in preparation). The program CGHviewer is 
available as a Windows executable coupled with an 
installer/uninstaller (Contact: carles@igbmc.u-strasbg.fr). 
CGHviewer allows the import o f text files. The human  
genom e annotation that has been integrated into the cur­
rent version o f CGHviewer comes from the June 2005 
assembly on the UCSC Genome Browser [23]. CGH­
viewer allows interactive graphical exploration o f individ­
ual arrays or groups o f arrays on genom ic or chromosomic 
scales. It also allows the detection and visualisation o f the 
BAC outliers. The visualisation o f the aCGH data is pro­
vided before and after segmentation by CBS [15]. CGH 
log-ratio values are all displayed as log2. For the genomic 
displays, the plots consist o f  a x-axis divided into 24 chro­
m osom es (22 chrom osomes plus chromosomes X and Y). 
CGHviewer provides a zoom -in option and a view-finder. 
Pointing at a measurement in a plot shows the coordi­
nates, and pointing at a box shows the "identity card" for 
BAC clones, oligonucleotide probes, genes and cyto- 
bands. The "identity card" includes information such as 
the accession number, the human genome position and 
for BACs and oligos, the log-ratio values.
Statistical methods
The autocorrelation for BACs and oligos has been com ­
puted using the formula £  ~ fi^  ~ fi) . Thei 6
autocorrelation measures the correlation in longitudinal 
data between a position x i and the next position xi+1. In 
this paper, x i and xi+1 correspond to consecutive BACs or 
oligos. d  and a  are respectively the mean and the standard 
deviation o f the n  log-ratios observed in a chromosome 
either for BAC or oligo aCGH. The lower the autocorrela­
tion, the higher the noise.
Kendall's correlation is a ranks correlation measure 
defined by t  = 2 P ( ( X 1  - X 2 ) ( Y 1  - Y 2 )  > 0) - 1. In case o f  
independence between variables X and Y, t  follows the
gaussian law N(0, 2(2n + 5) ) Tvaries between -1 and 1, ^ 9n(n +1)
and t  = 2P((X1 - X2)(Y1 - Y2) > 0) - 1 means that for two
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pairs ofvalues (X1, Y1) and (X2, Y2), i f X 2  is greater (resp. 
smaller) than X1, then Y2 is greater (resp. smaller) than Y1 
with a probability equal to P((X1 - X2)(Y1 - Y2) > 0).
The Circular Binary Segmentation m ethod is a change 
point analysis accessible through the DNAcopy, v1.1.2  
(R) library [15]. The parameters were chosen as follows: 
alpha = 0.01, number o f  permutations = 1000 and win­
dow size = 200 to increase the speed o f the algorithm.
The R language was used for all statistical tests and plots 
except for the detection o f  BAC outliers.
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